Lucid Diagnostics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lucid Diagnostics Inc. | ||
| March 25, 2024 | By: | /s/ Dennis M. McGrath |
|---|---|---|
| Dennis M. McGrath | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. Each person whose signature appears below hereby authorizes both Lishan Aklog, M.D. and Dennis M. McGrath or either of them acting in the absence of the others, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments to this report, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission.
| Signature | Title | Date |
|---|---|---|
| /s/ Lishan Aklog, M.D. | Chairman of the Board of Directors | March 25, 2024 |
| Lishan Aklog, M.D. | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| /s/ Dennis M. McGrath | Chief Financial Officer | March 25, 2024 |
| Dennis M. McGrath | (Principal Financial and Accounting Officer) | |
| /s/ Stanley N. Lapidus | Vice Chairman | March 25, 2024 |
| Stanley N. Lapidus | Director | |
| /s/ Debra J. White | Director | March 25, 2024 |
| Debra J. White | ||
| /s/ James L. Cox, M.D. | Director | March 25, 2024 |
| James L. Cox, M.D. | ||
| /s/ Jacque J. Sokolov, M.D. | Director | March 25, 2024 |
| Jacque J. Sokolov, M.D. | ||
| /s/ Ronald M. Sparks | Director | March 25, 2024 |
| Ronald M. Sparks | ||
LUCID DIAGNOSTICS INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Financial Statements | Page | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID #688) | F-2 | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 | |
| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 | |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2023 and 2022 | F-5 | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 | |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.